SecBot SecBot

BHC

Bausch Health Companies Inc.
NYSE· Pharmaceutical Preparations· Inc. NJ· CIK 0000885590 Biotech & Drug Discovery
$8.42 +0.07 (+0.84%)
Nov 16 4:00 PM ET · prev $8.35
Market cap
$3.1B
Mid cap
Consensus
Sell
0% Buy or better · 8 analysts
Median target
$8.00
−5% · range $7.00–10.00
1 year
+37.4%
from $6.13 · Nov 17
30 days
+33.2%
from $6.32
52-week range
$4.43–8.91
−5% from high · low Jul 24
Avg volume 20D
4.90M
Oct 29 spike 33.78M
Short interest
7.41M
≈2.0% of shares · −10.1%
Days to cover
1.2
at average volume
Insider net
−$506.7K
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 3 exits
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $506.7K.

  • InstitutionsMIXED

    Q3 2026: 23 added (0 new), 19 trimmed or exited.

  • AnalystsBEARISH

    0 of 8 rate it Buy or better. Median target $8.00 (−5%).

  • EstimatesRISING

    Current-quarter EPS estimate $1.274 → $1.309 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −10.1% to 7.41M shares. 1.2 days to cover, ≈2.0% of shares.

  • TrendUPTREND

    27% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q3 2026
0
new positions
3
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM3,296,234$26.8M
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDTRIM3,000,000$17.5M
MARSHALL WACE, LLPDOUBLED2,570,980$15.0M
RENAISSANCE TECHNOLOGIES LLCADD2,055,272$12.0M
MACKENZIE FINANCIAL CORPDOUBLED1,173,969$6.8M
Qube Research & Technologies LtdTRIM837,389$4.9M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED807,832$4.7M
Walleye Capital LLCDOUBLED657,339$3.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Sell 0% rate it Buy or better
Strong Buy0Buy0Hold4Sell3Strong Sell1
12-month targets · 5 analysts

Price is inside the target range. Median implies −5%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Barclays
MAINTAIN
MAINTAINEqual-Weight
Oct 29, 2026Jefferies
MAINTAIN
MAINTAINHold
Oct 29, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Reddit
Recent posts
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$506.7K
sold · 3 insiders
DateInsiderTypeValue
Sep 30, 2026
Paulson John
Director
Sep 30, 2026
AWARD$62.5K
Sep 30, 2026
LEUNG SANDRA
Director
Sep 30, 2026
AWARD$33.7K
Sep 30, 2026
WECHSLER AMY B
Director
Sep 30, 2026
AWARD$6.9K
Aug 19, 2026
Lenar Aimee J.
President, US Pharma
Aug 19, 2026
SELL$258.9K
Jul 17, 2026
Lenar Aimee J.
President, US Pharma
Jul 17, 2026
TAX W/H$25.4K
Jul 15, 2026
Lenar Aimee J.
President, US Pharma
Jul 15, 2026
TAX W/H$114.4K
Jul 14, 2026
LEE STEVEN HYOSIG
SVP, Controller & CAO
Jul 14, 2026
TAX W/H$14.8K
Jun 30, 2026
WECHSLER AMY B
Director
Jun 30, 2026
AWARD$6.9K

Earnings setup

Estimates
$1.31
EPS estimate, this quarter
+3%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$1.31$1.17–$1.49+0.8%$2.8B
Next Q🔒 Fresh data, subscribers only
Current FY$4.91$4.32–$5.33+9.7%$11.0B
Next FY$4.34$4.00–$4.77+3.5%$11.0B

Washington

Corporate Lobbying

6 lobbying filings and 1 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
7,409,975
shares short
-10.1%
vs prior settlement
1.2
days to cover
≈2.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 6, 2026 Other
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its g
Oct 28, 2026 SEC
Bausch Health reported Q3 2026 revenue of $2.94B (up 10% YoY) and adjusted EPS of $1.77, beating the $1.24 consensus…
8-K · Impact 6/10
Oct 28, 2026 Press
Bausch Health announced a $50 million share repurchase program to manage dilution from employee equity compensation…
Impact 3/10
Oct 6, 2026 SEC
Bausch Health Companies Inc. announced it will report its Q3 2026 results on October 28, 2026.
PRESS-RELEASE · Impact 1/10
Sep 30, 2026 Insider
Paulson John was granted 10,720 shares
Director @ $5.83 ($62.5K)
Sep 30, 2026 Insider
LEUNG SANDRA was granted 5,789 shares
Director @ $5.83 ($33.7K)
Sep 30, 2026 Insider
WECHSLER AMY B was granted 1,179 shares
Director @ $5.83 ($6.9K)
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · TRIM
3,296,234 shares ($26.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 6, 2026
Press release
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix…
Oct 28, 2026
Press release
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health…
Oct 28, 2026
Buyback
Bausch Health Announces US$50 Million Share Repurchase Program
LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized…
Oct 20, 2026
Clinical Trial
The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)
Phase 3 · COMPLETED
Oct 20, 2026
Clinical Trial
Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis
Phase 3 · COMPLETED

SecBot reports

3 filings · 2 press releases · 1 bullish · 0 bearish · 2 neutral
All BHC filing & press-release reports (5)